Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Wulf

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Pageof 14